GlassScriptPhysician profile
Fabio Volterra
NPI 1841289931
$1,085.76
in general payments reported to CMS, 2019-2025
26 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $65.35 · 2021: $235 · 2022: $70.82 · 2023: $472 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $263 · Food and Beverage: $173 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $262.50 |
| Food and Beverage | $172.96 |
| Education | $153.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $262.50 | 2023 | Scemblix |
| Janssen Biotech, INC. | $146.92 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $124.98 | 2023 | Epkinly |
| Exelixis INC. | $84.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $83.06 | 2019-2025 | Imfinzi |
| Kite Pharma, INC. | $73.13 | 2021-2025 | Yescarta |
| Ge Healthcare | $70.82 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $38.17 | 2020 | |
| Epizyme, INC. | $29.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.80 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.64 | 2019 | |
| Foundation Medicine, INC. | $18.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.93 | 2019 | |
| Advanced Accelerator Applications | $15.89 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $14.29 | 2019 | |
| Pfizer INC. | $13.75 | 2019 | |
| Merck Sharp & Dohme LLC | $12.60 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Seagen INC. | $11.29 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabio Volterra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.